Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of BIIB054 in Parkinson's Disease
2016-004610-95Phase 2Unknown
- Sponsor
- Biogen
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB054 active treatment with Placebo (2 arms). Primary endpoint: Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Status: unknown.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-004610-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004610-95.